Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 18/20 | 0.65 |
| ▸ | HCRTR2 | O43614 | 18/20 | 0.65 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9977839 | 0.90 | HCRTR1 (0.75) | HCRTR1HCRTR2 | |
| SCHEMBL9977818 | 0.86 | HCRTR1 (0.73) | HCRTR1HCRTR2 | |
| SCHEMBL9977849 | 0.81 | HCRTR1 (0.88) | HCRTR1HCRTR2 | |
| SCHEMBL15327049 | 0.80 | HCRTR1 (0.83) | HCRTR1HCRTR2 | |
| SCHEMBL9977841 | 0.79 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL9977866 | 0.78 | HCRTR1 (0.67) | HCRTR1HCRTR2 | |
| SCHEMBL15326988 | 0.78 | HCRTR1 (0.67) | HCRTR1HCRTR2 | |
| SCHEMBL9977848 | 0.77 | HCRTR1 (0.61) | HCRTR1HCRTR2NAMPT | |
| SCHEMBL9977847 | 0.76 | HCRTR1 (0.64) | HCRTR1HCRTR2 | |
| SCHEMBL9977836 | 0.76 | HCRTR1 (0.73) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | claimed |
| EP-2653469-A1 | PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-10-23 | — | — | EP | claimed |
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| EP-2653469-A1 | PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012081692-A1 | PYRAZOLE DERIVATIVE | 大正製薬株式会社 (JP) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | HCRTR1, HCRTR2, NPY4R | HCRTR1 1/4885HCRTR2 2/4885ALOX5AP 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.